Author(s):
Sejal Tukaram Patel, Harshada Kailas Patil, Hetakshi Vilas Patil, Mohit Sunil Pawar, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
Email(s):
sejalpatel1322001@gmail.com
DOI:
10.52711/2231-5675.2025.00035 
Address:
Sejal Tukaram Patel*, Harshada Kailas Patil, Hetakshi Vilas Patil, Mohit Sunil Pawar, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
P.S.G.V.P Mandal’s College of Pharmacy Shahada, Dist- Nandurbar-425409, Maharashtra-India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2024
ABSTRACT:
Fimasartan, an angiotensin II receptor blocker (ARB), is widely used for managing hypertension and cardiovascular disorders due to its high selectivity for the AT1 receptor. Ensuring its efficacy, safety, and regulatory compliance necessitates robust analytical methods for its quantification in bulk drugs and pharmaceutical formulations. High-Performance Liquid Chromatography (HPLC), Ultra-Performance Liquid Chromatography (UPLC), High-Performance Thin Layer Chromatography (HPTLC), and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) are some of the analytical methods used for Fimasartan that are examined in this review. These methods provide high sensitivity and accuracy, making them essential for stability testing, impurity profiling, and pharmacokinetic assessments. Additionally, UV-Visible spectrophotometry has been utilized for qualitative and quantitative analysis due to its simplicity and cost-effectiveness. Furthermore, a detailed compilation of reported analytical methods including stability-indicating HPLC, LC-MS/MS, and UPLC-MS/MS techniques developed and validated across various studies is presented, showcasing key parameters like precision, retention time, detection limits, and calibration ranges. Stability-indicating methods are emphasized for detecting degradation products under stress conditions, ensuring regulatory compliance. Validation parameters set by the International Council for Harmonisation (ICH), including accuracy, precision, robustness, and specificity, are discussed. Despite the effectiveness of current techniques, challenges such as high costs and labor-intensive procedures persist. Future trends focus on automation, green chemistry practices, and AI-driven method optimization, improving efficiency and sustainability in Fimasartan analysis.
Cite this article:
Sejal Tukaram Patel, Harshada Kailas Patil, Hetakshi Vilas Patil, Mohit Sunil Pawar, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. Analytical Methods for Fimasartan: A Comprehensive Review of Chromatographic and Spectroscopic Techniques. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):221-8. doi: 10.52711/2231-5675.2025.00035
Cite(Electronic):
Sejal Tukaram Patel, Harshada Kailas Patil, Hetakshi Vilas Patil, Mohit Sunil Pawar, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. Analytical Methods for Fimasartan: A Comprehensive Review of Chromatographic and Spectroscopic Techniques. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):221-8. doi: 10.52711/2231-5675.2025.00035 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-15-3-11
8. REFERENCES:
1. Mavromoustakos T, Agelis G, Durdagi S. AT1 antagonists: a patent review (2008 – 2012). Expert Opin Ther Pat. 2013 Nov; 23(11): 1483–94.
2. Spasov AA, Yakovlev DS, Brigadirova AA. Angiotensin AT1 Receptors and Their Ligands (Review). Pharm Chem J. 2017 Apr; 51(1): 1–8.
3. Gao Q, Xu L, Cai J. New drug targets for hypertension: A literature review. Biochim Biophys Acta BBA-Mol Basis Dis. 2021; 1867(3): 166037.
4. Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation. 2001 Feb; 103(6): 904–12.
5. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat Rev Nephrol. 2014; 10(6): 325–46.
6. Finotti Cordeiro C, Lopardi Franco L, Teixeira Carvalho D, Bonfilio R. Impurities in Active Pharmaceutical Ingredients and Drug Products: A Critical Review. Crit Rev Anal Chem. 2024 Jul 26; 1–21.
7. Niranjan PK, Bahadur S. Recent Developments in Drug Targets and Combination Therapy for the Clinical Management of Hypertension. Cardiovasc Haematol Disord-Drug Targets Former Curr Drug Targets-Cardiovasc Hematol Disord. 2023; 23(4): 226–45.
8. Gude D. How full is our antihypertensives pipeline? J Pharmacol Pharmacother. 2012 Mar; 3(1): 7–11.
9. Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, et al. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 2020 Feb; 43(2): 99–107.
10. Choi Y, Lee S, Jang IJ, Yu KS. Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers. Drug Des Devel Ther. 2018 Jul 24; 12: 2301–9.
11. Keller F, Maiga M, Neumayer HH, Lode H, Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet. 1984; 9(3): 275–82.
12. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci. 2021 Nov 26; 22(23): 12808.
13. Kim S, Lee J, Shin D, Lim KS, Kim YS, Jang IJ, et al. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study. Drug Des Devel Ther. 2014 Oct 6; 8: 1723–31.
14. Balakumar P, Jagadeesh G. Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. In: Jagadeesh G, Balakumar P, Maung-U K, editors. Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Cham: Springer International Publishing; 2015 p. 751–806.
15. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(6): 572–86.
16. Pandya CP. Development of Stability Indicating Assay Method and Study of Degradation Behaviour of Some Drugs and Formulation [Internet] [PhD Thesis]. Maharaja Sayajirao University of Baroda (India); 2020 Shodhganga 2022 p. 512–525.
17. Yoon SH, Oh S, Kim HS, Yi S, Yu KS, Jang IJ, et al. Validated LC–MS/MS Assay for the quantitative determination of Fimasartan in human plasma: application to pharmacokinetic studies. J Chromatogr Sci. 2015; 53(8): 1250–6.
18. Nikolin B, Imamović B, Medanhodzić-Vuk S, Sober M. High perfomance liquid chromatography in pharmaceutical analyses. Bosn J Basic Med Sci. 2004 May; 4(2): 5–9.
19. Ultra Performance Liquid Chromatography - an overview | ScienceDirect Topics. 2023 May; 4(2): 5–9.
20. Holkar GS, Waghmare SA. Development And Validation Of RP-HPLC Method For Determination of Fimasartan in Bulk and Their Dosage Form – A Review. Int J Pharm Sci. 2024 Jan 7; 02(06).
21. Loescher CM, Morton DW, Razic S, Agatonovic-Kustrin S. High performance thin layer chromatography (HPTLC) and high-performance liquid chromatography (HPLC) for the qualitative and quantitative analysis of Calendula officinalis-advantages and limitations. J Pharm Biomed Anal. 2014 Sep; 98: 52–9.
22. Pitt JJ. Principles and Applications of Liquid Chromatography-Mass Spectrometry in Clinical Biochemistry. Clin Biochem Rev. 2009 Feb; 30(1): 19–34.
23. Zuo H, Li T, Zhang D, Ma J, Zhang Z, Ou Y, et al. Enhancing Chromatographic Performance of Immobilized Angiotensin II Type 1 Receptor by Strain-Promoted Alkyne Azide Cycloaddition through Genetically Encoded Unnatural Amino Acid. Anal Chem. 2022 Nov 15; 94(45): 15711–9.
24. Khokrale S, Lulla J, Borse L. A Review of The UV-Visible Spectroscopy’s Method Development And Validation. Int J Pharm Sci. 2024 Oct 6; 02(05): 1–1.
25. UV-Visible Spectroscopy - an overview | ScienceDirect Topics. 2012 Oct 11; 02(05): 7–7.
26. ICH Q2(R2) Validation of analytical procedures - Scientific guideline | European Medicines Agency (EMA). 2024-2025 Jan 11
27. Lavanya, C. G., et al. "Analytical method validation parameters—An updated review." Int. J. Pharm. Sci. Rev. Res 61 (2020): 1-7.
28. Shin BS, Kim TH, Paik SH, Chi YH, Lee JH, Tan HK, et al. Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr BMC. 2011 Nov; 25(11): 1208–14.
29. Kormány R, Fekete J, Guillarme D, Fekete S. Reliability of simulated robustness testing in fast liquid chromatography, using state-of-the-art column technology, instrumentation and modelling software. J Pharm Biomed Anal. 2014 Feb 15; 89: 67–75.
30. Holčapek M, Kolářová L, Nobilis M. High-performance liquid chromatography–tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. Anal Bioanal Chem. 2008 May; 391(1): 59–78.
31. Moon HW, Yousaf AM, Cho KH, Yong CS, Kim JO, Choi HG. Evaluation of stability and simultaneous determination of fimasartan and amlodipine by a HPLC method in combination tablets. Asian J Pharm Sci [Internet]. 2014 Jun [cited 2025 Feb 27]; 9(3): 123–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1818087614000208
32. Yoon SH, Oh S, Kim HS, Yi S, Yu KS, Jang IJ, et al. Validated LC–MS/MS Assay for the Quantitative Determination of Fimasartan in Human Plasma: Application to Pharmacokinetic Studies. J Chromatogr Sci. 2015 Feb 27]; 53(8): 1250–6
33. Liu H, Ma Y, Tian W, Li Q, Wu Z, Wang M, Liu X, Zheng X, Han X. Development and validation of a UPLC-MS/MS method for rapid and simultaneous quantification of BPI-460372 and its metabolites BPI-460444 and BPI-460456 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Oct 15; 1247: 124300. doi: 10.1016/j.jchromb.2024.124300. Epub 2024 Sep 8. PMID: 39265487.
34. Pandya CP, Rajput DSJ. Validated Stability Indicating RP-HPLC Method For The Determination Of Fimasartan In Presence Of Degradation Products. 7(11). 53(8): 12174–6
35. Badade S, Dole M, Wagh V. Development and validation of HPTLC method for determination of fimasartan in bulk and pharmaceutical dosage form. 2019;8.
36. Mohammad SS, Avutu SL, Marreddy JL. Development And Validated Uv Spectrophotometric Method For The Estimation Of Fimasartan In Pure And Pharmaceutical Dosage Forms. 2019;5(4).
37. A S, Prasad Panigrahy U. Stability Indicating Method Development And Validation Of Fimasartan By Reverse-Phase High-Performance Liquid Chromatography In Bulk And Pharmaceutical Dosage Form. Asian J Pharm Clin Res. 2021 Feb 7; 138–46.
38. Nirma C, Kumar DS. Stability Indicating Rp-Hplc Method Development And Validation For The Combination Of Rosuvastatin And Fimasartan In Synthetic Mixture. 2022; 10(10).
39. Singh S, Khan MA, Rathod N, Parmar D, Rathva D, Dalwadi M, et al. Development & Validation of UV Spectrophotometric Method for Simultaneous Estimation of Cilnidipine & Fimasartan In Synthetic Mixture. 10(4).
40. Dhaware A, Dhudhal B. Analytical Method Development and Validation for Assay of Fimasartan Potassium Trihydrate and Chlorthalidone in Tablet Dosage Form by Using RP- HPLC. 5(4).
41. Gajre R, Dedania DZ, Jain DV. RP HPLC method development and validation for Fimasartan and Chlorthalidone. 11(2).